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Abstract
Background: Abnormalities of chromosome 22q11, including deletions and translocations, have been described in
association with different birth defects and malformations occurring in many combinations and degrees of severity.
Case presentation: We describe the case of an 8 month-old infant with no dysmorphic signs who showed
progressive postnatal growth failure and no chronic systemic diseases. We found a 22q11.2 microdeletion, inherited
from the mother, suggesting the diagnosis of DiGeorge syndrome. The patient had an isolated growth hormone
(GH) deficiency and a significant increase in linear growth during the first and the second year of GH therapy, and a
recovery of weight was shown.
Conclusions: Sometimes, in infants with growth failure a genetic analysis is strongly suggested, since chromosomal
abnormalities may be present.
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Background
Abnormalities of chromosome 22q11, including dele-
tions and translocations, have been described in associ-
ation with different birth defects and malformations
occurring in many combinations and degrees of severity
[1]. In particular, deletion of chromosome 22q11.2 is
causally related to DiGeorge syndrome (DGS) [1], velo-
cardiofacial syndrome (VCFS) [2] and conotruncal
anomaly face syndromes [3]. The prevalence of these
22q11 deletion syndromes (DS) is about 1/1,000 foe-
tuses, according to the study of Grati et al. [4]. Although
many patients are diagnosed before age 2 years, the diag-
nosis during childhood and even adulthood is not so
rare, also due to changing of phenotypes associated with
these syndromes. Although cardiac malformations and
immunodeficiency are the cardinal manifestations [5],
short stature is a common problem associated with
22q11.2 microdeletion syndrome [6], also in the absence
of cardiac defects. Many studies reported growth
retardation and short stature in children with DGS/
VCFS [7, 8], and in some cases growth hormone defi-
ciency (GHD) was also diagnosed [7].
Here, we describe a short infant who was investigated
because of a progressive failure to thrive. After exclusion
of chronic systemic diseases, a genetic analysis was re-
quested although no particular syndromic signs were
present and a diagnosis of DiGeorge syndrome was
made.
Case presentation
An 8 month-old girl, the only child of non-consanguineous
healthy parents was referred to our Department because of
failure to thrive (height: 64.3 cm, −2.12 standard deviation
score (SDS); weight: 5,680 g, body mass index (BMI) 0.57
SDS according to Cole). She was born by caesarean section
at the 39th week for interruption of foetal growth, with a
birth weight of 2,450 g (BMI −1.82 SDS) and length of
47 cm (−1.26 SDS). Apgar score was not available, but
spontaneous breathing, without cyanosis and jaundice, was
documented.
No increase in weight was observed after a period of
adequate diet and supplementation of vitamins. Systemic
diseases including hypothyroidism, skeletal dwarfism
and malabsorption, in particular celiac disease, and com-
mon syndromes, such as Turner, were excluded.
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Her progressive growth failure, which is typical of
primitive dwarfism, led us to investigate the subject from
a genetic point of view, although no dysmorphic signs
were present. The comparative genomic hybridization
array (array-CGH) showed a 17q12 duplication of ap-
proximately 692 kb, with no pathogenetic significance,
and a 22q11.2 deletion of approximately 2.57 Mb. A
diagnosis of 22q11.2DS was therefore made, in the ab-
sence of typical features of this syndrome [9]. In fact,
thyroid-parathyroid ecocolordoppler and complete abdo-
men ultrasound were normal. The echocardiography
showed the presence of patent foramen ovale with left to
right shunt without hemodynamic significance. Both
humoral and cellular immune system was found to be
normal, confirming the absence of systemic infections.
Finally, no otolaryngologic, immunologic and neurocog-
nitive problems were reported. The mother showed the
same deletion as her own child, notwithstanding normal
phenotype and only some relatively modest learning and
behavioural problems, such as mild cognitive deficit,
borderline intellectual function, poor social skills and
unipolar mood. She was therefore given genetic counsel-
ling, since she was interested in having another child.
At the age of 14 months, the patient presented a height
of 70.5 cm (−2.19 SDS), a weight of 7320 g (BMI: −2.05
SDS), and a bone age of 8 months. At the age of
24 months, her length was 79 cm (−1.68 SDS) and weight
8300 (BMI −2.86 SDS). Therefore, because of the progres-
sive growth failure, she underwent a careful endocrine
evaluation that showed an insufficient GH response to two
pharmacological stimuli (GH peaks: 4.3 ng/ml and 8 ng/
ml; normal values >10 ng/ml). According to our national
rules, arginine infusion was administered on two different
days to avoid side effects due to the age and weight of the
patient. Low serum insulin-like growth factor-I (IGF-I)
value (38.7 ng/ml, −3.19 SDS) confirmed the diagnosis of
GHD. Brain magnetic resonance image (MRI) documented
a normal morphology; in particular, morphologically nor-
mal adenohypophysis, in place neurohypophysis keeping
regular signal hyperintensity and aligned pituitary stalk.
The replacement therapy with GH (0.21 mg/Kg/week di-
vided in six weekly doses) was promptly started at
25 months of life. A significant increase in linear growth
was observed during the first and the second year of ther-
apy (growth rate: 8.04 cm/year, 0.19 SDS and 8.79 cm/year,
1.67 SDS, respectively), as shown in Fig. 1.
Furthermore, a recovery of the weight defect was ob-
served already after the 1st year of GH treatment,
independently of food intake (age 3.1 years, height
87.6 cm, −1.66 SDS; weight 12 Kg, BMI −0.16 SDS).
Discussion
Chromosome 22q11 microdeletion could be associated
with DGS, VCFS [10], conotruncal anomaly face
syndrome (CTAF) [11], autosomal dominant Optiz G/
BBB [12] and Cayler Cardiofacial syndrome [13].
These syndromes are characterized by an enormous
phenotypic heterogeneity. The most frequent feature
is the association of congenital cardiac abnormalities
and neonatal hypocalcaemia (more than 70 % of pa-
tients) which leads to the diagnosis in the first
months of life [14]. Moreover, a thymus hypoplasia
can be found in these subjects with consequent im-
munodeficiency (75 % of the patients) [10, 15]. Devel-
opmental delay, facial dysmorphia, palatal anomalies,
feeding difficulties and other clinical features are also
seen in most infants, but are less consistent and not
easily recognized in children [15, 16]. Short stature is
one of these features and has been related to a con-
stitutional delay [7]. When multiple defects and/or
features commonly seen in the syndrome are present
simultaneously in a child, the decision to check
22q11.2 deletion is often straightforward. On the con-
trary, signs and symptoms might sometimes be subtle
and could be easily overlooked, so that many patients
remain undiagnosed.
Our patient had none of the characteristic clinical fea-
tures of the syndrome. However, her progressive growth
failure, which is typical in primitive dwarfism, led us to
investigate the subject from a genetic point of view,
using the array-CGH analysis. We found the 22q11.2 de-
letion, which could not be suspected on the basis of clin-
ical symptoms alone. In infants showing progressive
growth failure, we therefore suggest that a careful clin-
ical and laboratory investigation to exclude congenital
malformations and chronic diseases is mandatory. Then,
after these conditions have been excluded, a genetic ana-
lysis to find chromosomal abnormalities responsible for
failure to thrive is important, notwithstanding the lack
of a suggestive family history and dysmorphic facial fea-
tures. An early diagnosis of 22q11.2 syndrome is import-
ant in order to act on symptoms such as growth
development or speech and language delay and to avoid
conditions which may develop during adulthood, espe-
cially behavioural and psychiatric disorders [17]. In fact,
patients with 22q11 deletion perform worse in neuro-
cognitive tests such as verbal memory [18] and spatial
working memory [19] after the onset of psychosis.
Psychotic disorder is associated with a deterioration of
social and academic skills [20] as well as a deficit of
intelligence quotient (IQ).
Furthermore, once the diagnosis has been made in a
child, it is necessary to extend the genetic investigation
to the patient’s parents, although they are asymptomatic,
because 10 % of the typical mutations of the syndrome
are inherited from an affected parent [21]. It is therefore
necessary to broaden the index of suspicion, particularly
in the parents of affected probands, in order to identify
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mildly affected individuals with the 22q11.2 deletion
which will ultimately lead to appropriate cognitive re-
mediation, medical management, and recurrence risk
counselling for these families. Clinicians should be aware
that the deletion is more common than has been previ-
ously reported.
Moreover, this baby showed non-severe isolated GHD
and promptly started GH substitutive treatment in order
to improve her height and weight. The condition of
GHD in patients with 22q11.2 microdeletion has rarely
been reported [22] and was generally found in children
who were significantly below the 5th percentile for height
[23]. No explanation was hypothesized to explain this as-
sociation. Replacement therapy in GHD children with a
22q11.2 deletion induces a sustained improvement in
height and growth velocity [22]. Therefore, in children
with the 22q11.2 deletion and short stature/poor growth,
GHD should be suspected.
Conclusions
In conclusion, we report the case of a child who
showed failure to thrive not associated with any dys-
morphic feature, in whom deletion of chromosome
22q11.2 was found, suggesting the diagnosis of
DiGeorge syndrome.
Since it is now being increasingly recognized that
many patients with failure to thrive may have chromo-
somal abnormalities, we strongly believe that genetic
analysis such as array-CGH in this field may improve
the clinician’s ability to diagnose congenital causes of
short stature. The identification of a molecular aetiology
for short stature can end the diagnostic workup for a pa-
tient, provide the family with an answer as to why their
child is not growing normally and alert the clinician to
other medical comorbidities. Furthermore, determin-
ation of a particular genetic abnormality is invaluable for
genetic counselling.
Fig. 1 Height curve of the subject. The arrow indicates the start of GH substitutive therapy
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